Program
mufemilast
Also written as “Hemay005”, “Hemay005 tablet” and “Hemay005 tablets”.
Its studies are mostly in Psoriasis · Colitis, Ulcerative · Pulmonary Disease, Chronic Obstructive · Behcet Syndrome · Dermatitis, Atopic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ganzhou Hemay Pharmaceutical | 115 open or running | phase 3since Nov 17, 2023 | Jun 15, 2022 | Dec 30, 2026phase 2 · NCT05486104 |
| Tianjin Hemay Pharmaceutical | 50 open or running | phase 3since Apr 1, 2021 | Mar 20, 2019 | none ahead |
| Tianjin Hemay Bio-Tech | 30 open or running | phase 1since Dec 22, 2016 | Dec 22, 2016 | none ahead |
| Anhui Hemay Pharmaceutical | 10 open or running | phase 1since Mar 18, 2025 | Mar 18, 2025 | none ahead |
Also a collaborator on its studies: hemay-pharmaceutical-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Dec 22, 2016.
- Oct 19, 2020Phase 2 study in Behcet SyndromeTianjin Hemay Pharmaceutical · NCT04609397 · 89 enrolled · China
- Apr 1, 2021Phase 3 study in PsoriasisTianjin Hemay Pharmaceutical · NCT04839328 · 306 enrolled · China
- Apr 7, 2021Phase 1 study in PsoriasisTianjin Hemay Pharmaceutical · NCT04837235 · 12 enrolled · China
- May 30, 2022Phase 2 study in Active Ankylosing SpondylitisTianjin Hemay Pharmaceutical · NCT05407246 · 90 enrolled · China
- Jun 15, 2022Ganzhou Hemay Pharmaceutical's first study: phase 1 study in Health VolunteerNew to Ganzhou Hemay PharmaceuticalGanzhou Hemay Pharmaceutical · NCT05468645 · 6 enrolled · China
- Aug 1, 2022Phase 2 study in Moderate to Severe Ulcerative ColitisGanzhou Hemay Pharmaceutical · NCT05486104 · 92 enrolled · China
- Mar 3, 2023Phase 2 study in Dermatitis, AtopicGanzhou Hemay Pharmaceutical · NCT05769946 · 79 enrolled · China
- Apr 5, 2023Phase 1 study in HealthyGanzhou Hemay Pharmaceutical · NCT05941247 · 12 enrolled · Australia
- Nov 17, 2023Phase 3 study in Behcet SyndromeGanzhou Hemay Pharmaceutical · NCT06145893 · 162 planned · China
- Apr 9, 20242 phase 1 studies in PsoriasisGanzhou Hemay Pharmaceutical · NCT06380153, NCT06376474
- Sep 20, 20242 phase 1 studies in PsoriasisGanzhou Hemay Pharmaceutical · NCT06610903, NCT06610890
- Mar 18, 2025Anhui Hemay Pharmaceutical's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Anhui Hemay PharmaceuticalAnhui Hemay Pharmaceutical · NCT06908642 · 468 enrolled · China
- Dec 18, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveGanzhou Hemay Pharmaceutical · NCT07314242 · 120 planned · China
- Jun 3, 2026Phase 3 study in Colitis, UlcerativeGanzhou Hemay Pharmaceutical · NCT07650942 · 360 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 2 study in Moderate to Severe Ulcerative ColitisGanzhou Hemay Pharmaceutical · NCT05486104
- Dec 31, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveGanzhou Hemay Pharmaceutical · NCT07314242
- May 2028Primary completion: phase 3 study in Colitis, UlcerativeGanzhou Hemay Pharmaceutical · NCT07650942
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07650942Colitis, Ulcerative · China | 3 | Not yet recruiting | Ganzhou Hemay Pharmaceutical | May 2028 | 360 |
| NCT07314242Pulmonary Disease, Chronic Obstructive · China | 2 | Not yet recruiting | Ganzhou Hemay Pharmaceutical | Dec 31, 2027 | 120 |
| NCT06908642Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Anhui Hemay Pharmaceutical | Jun 3, 2025 | 468 |
| NCT06610903Psoriasis · China | 1 | Completed | Ganzhou Hemay Pharmaceutical | Sep 30, 2024 | 28 |
| NCT06610890Psoriasis · China | 1 | Completed | Ganzhou Hemay Pharmaceutical | Jan 20, 2025 | 20 |
| NCT06380153Psoriasis · China | 1 | Completed | Ganzhou Hemay Pharmaceutical | Apr 16, 2025 | 26 |
| NCT06376474Psoriasis · China | 1 | Recruiting | Ganzhou Hemay Pharmaceutical | Dec 10, 2025 | 24 |
| NCT06145893Behcet Syndrome · China | 3 | Recruiting | Ganzhou Hemay Pharmaceutical | May 30, 2026 | 162 |
| NCT05941247Healthy · Australia | 1 | Completed | Ganzhou Hemay Pharmaceutical | Aug 8, 2023 | 12 |
| NCT05769946Dermatitis, Atopic · China | 2 | Completed | Ganzhou Hemay Pharmaceutical | Jan 24, 2024 | 79 |
| NCT05486104Moderate to Severe Ulcerative Colitis · China | 2 | Active, not recruiting | Ganzhou Hemay Pharmaceutical | Dec 30, 2026 | 92 |
| NCT05468645Health Volunteer · China | 1 | Completed | Ganzhou Hemay Pharmaceutical | Sep 1, 2022 | 6 |
| NCT05407246Active Ankylosing Spondylitis · China | 2 | Completed | Tianjin Hemay Pharmaceutical | Aug 18, 2023 | 90 |
| NCT04837235Psoriasis · China | 1 | Completed | Tianjin Hemay Pharmaceutical | Aug 1, 2021 | 12 |
| NCT04839328Psoriasis · China | 3 | Completed | Tianjin Hemay Pharmaceutical | Oct 25, 2022 | 306 |
| NCT04609397Behcet Syndrome · China | 2 | Terminated | Tianjin Hemay Pharmaceutical | Apr 30, 2022 | 89 |
| NCT04102241Psoriasis · China | 2 | Completed | Tianjin Hemay Pharmaceutical | Oct 12, 2020 | 216 |
| NCT03577626Psoriasis | 1 | UNKNOWN | Tianjin Hemay Bio-Tech | Nov 10, 2018 | 12 |
| NCT03570346Psoriasis · China | 1 | UNKNOWN | Tianjin Hemay Bio-Tech | Oct 20, 2018 | 24 |
| NCT03007810Psoriasis · China | 1 | Completed | Tianjin Hemay Bio-Tech | Jun 2018 | 68 |
How it is read
Names in the registry
- “Hemay005”, 15 entries
- “Hemay005 tablet”, 3 entries
- “Hemay005 tablets”, 2 entries
- “Hemay005 60 mg”, 1 entry
- “[14C]Hemay005”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 10 studies
- Colitis, Ulcerative, 2 studies
- Pulmonary Disease, Chronic Obstructive, 2 studies
- Behcet Syndrome, 2 studies
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.